Your browser doesn't support javascript.
loading
Development of a CHO cell line for stable production of recombinant antibodies against human MMP9.
Ryu, Jina; Kim, Eun-Jung; Kim, Joo-Kyung; Park, Tai Hyun; Kim, Byung-Gee; Jeong, Hee-Jin.
  • Ryu J; Interdisciplinary Program in Bioengineering, Seoul National University, Seoul, 08826, Republic of Korea.
  • Kim EJ; School of Chemical and Biological Engineering, Institute of Chemical Processes, Seoul National University, Seoul, 08826, Republic of Korea.
  • Kim JK; Interdisciplinary Program in Bioengineering, Seoul National University, Seoul, 08826, Republic of Korea.
  • Park TH; Interdisciplinary Program in Bioengineering, Seoul National University, Seoul, 08826, Republic of Korea.
  • Kim BG; School of Chemical and Biological Engineering, Institute of Chemical Processes, Seoul National University, Seoul, 08826, Republic of Korea.
  • Jeong HJ; BioMAX/N-Bio Institute, Institute of Bioengineering, Seoul National University, Seoul, 08826, Republic of Korea.
BMC Biotechnol ; 22(1): 8, 2022 03 07.
Article en En | MEDLINE | ID: mdl-35255869
ABSTRACT

BACKGROUND:

Human matrix metalloproteinase 9 (hMMP9) is a biomarker in several diseases, including cancer, and the need for developing detectors and inhibitors of hMMP9 is increasing. As an antibody against hMMP9 can be selectively bound to hMMP9, the use of anti-MMP9 antibody presents new possibilities to address hMMP9-related diseases. In this study, we aimed to establish a stable Chinese hamster ovary (CHO) cell line for the stable production of antibodies against hMMP9.

RESULTS:

Weconstructed recombinant anti-hMMP9 antibody fragment-expressing genes and transfected these to CHO cells. We chose a single clone, and successfully produced a full-sized antibody against hMMP9 with high purity, sensitivity, and reproducibility. Subsequently, we confirmed the antigen-binding efficiency of the antibody.

CONCLUSIONS:

We developed a novel recombinant anti-hMMP9 antibody via a CHO cell-based mammalian expression system, which has a high potential to be used in a broad range of medical and industrial areas.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Metaloproteinasa 9 de la Matriz Límite: Animals / Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Metaloproteinasa 9 de la Matriz Límite: Animals / Humans Idioma: En Año: 2022 Tipo del documento: Article